Focus on myeloproliferative diseases and myelodysplastic syndromes.
Van Etten
Richard A
RA
Molecular Oncology Research Institute, Tufts-New England Medical Center, Boston, MA 02111, USA. rvanetten@tufts-nemc.org
Shannon
Kevin M
KM
D000753:Anemia, Refractory / Q000235:genetics / Q000473:pathology / Q000628:therapy; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000068877:Imatinib Mesylate; D015477:Leukemia, Myelomonocytic, Chronic / Q000235:genetics / Q000473:pathology / Q000628:therapy; D008954:Models, Biological; D009190:Myelodysplastic Syndromes / Q000235:genetics / Q000473:pathology* / Q000628:therapy; D009196:Myeloproliferative Disorders / Q000235:genetics / Q000473:pathology* / Q000628:therapy; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D015398:Signal Transduction / Q000235:genetics
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate